




PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO				Complete If Known (See R/T Patent)	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/728078
				Filing Date	December 3, 2003
				First Named Inventor	Dasa Lipovsek
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	4	Attorney Docket Number	COTH-P04-507

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
H	AA	5,235,041	08-10-1993	Cappello et al.	
	AB	5,514,581	05-07-1996	Ferrari et al.	
	AC	5,545,620	08-13-1996	Wahl et al.	
	AD	5,641,648	06-24-1997	Ferrari et al.	
	AE	5,770,697	06-23-1998	Ferrari et al.	
	AF	5,792,742	08-11-1998	Gold et al.	
	AG	6,018,030	01-25-2000	Ferrari et al.	
H	AH	6,462,189-B1	10-08-2002	Koide	
	AI	2002/0019517-A1	02-14-2002	Koide	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	AJ	WO 98/31700	07-23-1998			
	AK	WO 98/56915	12-17-1998			
	AL	WO 00/34784	06-15-2000			
	AM	WO 02/04523-A2	01-17-2002			



*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
H		Baron et al. H NMR Assignment and Secondary Structure of the Cell Adhesion Type III Module of Fibronectin. Biochemistry 31, 2068-2073 (1992).	
		Bianchi et al. High Level Expression and Rational Mutagenesis of a Designed Protein, the Minibody. J. Mol. Biol. 236, 649-659 (1994).	
		Boder et al. Yeast Surface Display for Screening Combinatorial Polypeptide Libraries. Nat. Biotech. 15, 553-557 (1997).	
		Bork and Doolittle. Proposed Acquisition of an Animal Protein Domain by Bacteria. PNAS 89, 8990-94 (1992).	
		Campbell et al. Building Proteins with Fibronectin Type III Modules. Structure 2, 333-337 (1994).	
		Clackson et al. Making Antibody Fragments Using Phage Display Libraries. Nature 352, 624-628 (1991).	

Examiner Signature		Date Considered	05/05
--------------------	--	-----------------	-------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/728078
				Filing Date	December 3, 2003
				First Named Inventor	Dasa Lipovsek
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	4	Attorney Docket Number	COTH-P04-507

	Clackson and Wells. In Vitro Selection from Protein and Peptide Libraries. TIB TECH 12, 173-184 (1994).	
	Clarke et al. Folding and Stability of a Fibronectin Type III Domain of Human Tenascin. J. Mol. Biol. 270, 771-778 (1997).	
	Copie et al. Solution Structure and Dynamics of Linked Cell Attachment Modules of Mouse Fibronectin Containing the RGD and Synergy Regions: Comparison with the Human Fibronectin Crystal Structure. J. Mol. Biol. 277, 663-682 (1998).	
	Cota et al. Two Proteins with the Same Structure Respond Very Differently to Mutation: The Role of Plasticity in Protein Stability. J. Mol. Biol. 302, 713-725 (2000).	
	Dickinson et al. Crystal Structure of the Tenth Type III Cell Adhesion Module of Human Fibronectin. J. Mol. Biol. 236, 1079-1092 (1994).	
	Dickinson et al. Crystals of the Cell-Binding Module of Fibronectin Obtained from a Series of Recombinant Fragments Differing in Length. J. Mol. Biol. 238, 123-127 (1994).	
	Ely et al. Common Molecular Scaffold for two Unrelated RGD Molecules. Prot. Eng. 8, 823-827 (1995).	
	Ghosh et al. Structure of NF-KB p50 Homodimer Bound to a kB Site. Nature 373, 303-310 (1995).	
	Grant et al. Structural Requirements for Biological Activity of the Ninth and Tenth Fill Domains of Human Fibronectin. J. Biol. Chem. 272, 6159-6166 (1997).	
	Hamers-Casterman et al. Naturally Occurring Antibodies Devoid of Light Chains. Nature 363, 446-448 (1993).	
	Hocking et al. A Novel Role for the Integrin-Binding III-10 Module in Fibronectin Matrix Assembly. J. Cell Biol. 133, 431-444 (1996).	
	Hocking et al. Activation of Distinct Alpha5Beta1-Mediated Signalling Pathways by Fibronectin's Cell Adhesion and Matrix Assembly Domains. J. Cell. Biol. 141, 241-253 (1998).	
	Hynes. Integrins: Versatility, Modulation, and Signaling in Cell Adhesion. Cell 69, 11-25 (1992).	
	Kohler and Milstein. Continuous Cultures of Fused Cells Secreting Antibody of Preddefined Specificity. Nature 256, 495-497 (1975).	
	Koide et al. Directed Evolution of Fibronectin Type III Domain to Novel Ligand Binding Proteins. FASEB J. 11(9), Supp., Abstract M40.	
	Koide et al. The Fibronectin Type III Domain as a Scaffold for Novel Binding Proteins. J. Mol. Biol. 284, 1141-1151 (1998).	
	Koide et al. Directed Evolution of Fibronectin Type III Domain to Novel Ligand Binding Proteins. Designing Small and Large Molecules I, Abstract 1739.	

Examiner Signature		Date Considered	05/05
--------------------	-------------------------------------------------------------------------------------	-----------------	-------



Substituta for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/728078	
			Filing Date	December 3, 2003	
			First Named Inventor	Dasa Lipovsek	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
			Attorney Docket Number	COTH-P04-507	
Sheet	3	of	4		

1		Ku and Schultz. Alternate Protein Frameworks for Molecular Recognition. PNAS 92, 6552-6556 (1995).	
2		Leahy et al. Structure of a Fibronectin Type III Domain from Tenascin Phased by MAD Analysis of the Selenomethionyl Protein. Science 258, 987-991 (1992).	
3		Lee et al. Strong Inhibition of Fibrogen Binding to Platelet Receptor Alpha2b beta 3 by RGD Sequences Installed into a Presentation Scaffold. Prot. Eng. 6, 745-754 (1993).	
4		Litvinovich and Ingham. Interactions Between Type III Domains in the 110 kDa Cell-Binding Fragment of Fibronectin. J. Mol. Biol. 248, 611-626 (1995).	
5		Lombardo et al. Conformational Flexibility and Crystallization of Tandemly Linked Type III Modules of Human Fibronectin. Prot. Sci. 5, 1934-1938 (1996).	
6		Main et al. The Three-Dimensional Structure of the Tenth Type III Module of Fibronectin: An Insight into RGD-Mediated Interactions. Cell 71, 671-678 (1992).	
7		Markland et al. Iterative Optimization of High-Affinity Protease Inhibitors Using Phage Display. 1. Plasmin. Biochemistry 35, 8045-8057 (1996).	
8		Markland et al. Iterative Optimization of High-Affinity Protease Inhibitors Using Phage Display. 2. Plasma Kallikrein and Thrombin. Biochemistry 35, 8058-8067 (1996).	
9		McConnell and Hoess. Tendamistat as a Scaffold for Conformationally Constrained Phage Peptide Libraries. J. Mol. Biol. 250, 460-470 (1995).	
10		Meinke et al. Cellulose-Binding Polypeptides from Cellulomonas fimi: Endoglucanase D (CenD), a Family A Beta-1, 4-Glucanase. J. Bacteriol. 175, 1910-1918 (1993).	
11		Muller et al. Structure of the NF-kB p50 Homodimer Bound to DNA. Nature 373, 311-317 (1995).	
12		Ngo et al. "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox" in the Protein Folding Problem and Tertiary Structure Prediction, Merz & Le Grand, ed. Birkhauser, Boston, p. 491-495 (1994).	
13		Nord et al. Binding Proteins Selected from Combinatorial Libraries of an Alpha-Helical Bacterial Receptor Domain. Nat. Biotech. 15, 772-777 (1997).	
14		Nord et al. A Combinatorial Library of an Alpha-Helical Bacterial Receptor Domain. Prot. Eng. 8, 601-608 (1995).	
15		Nygren and Uhlen. Scaffolds for Engineering Novel Binding Sites in Proteins. Curr. Op. Struc. Biol. 7, 463-469 (1997).	
16		Plaxco et al. Rapid Refolding of a Proline-Rich All-Beta-Sheet Fibronectin Type III Module. PNAS 93, 10703-10706 (1996).	
17		Plaxco et al. A Comparison of the Folding Kinetics and Thermodynamics of Two Homologous Fibronectin Type III Modules. J. Mol. Biol. 270, 763-770 (1997).	

Examiner Signature	Date Considered 05/05
--------------------	--------------------------------------------------------------------------------------


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/728078
				Filing Date	December 3, 2003
				First Named Inventor	Dasa Lipovsek
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	4	of	4	Attorney Docket Number	COTH-P04-507

	Potts and Campbell. Fibronectin Structure and Assembly. Curr. Opin. Cell Biol. 6, 648-655 (1994).	
	Potts and Campbell. Structure and Function of Fibronectin Modules. Matrix Biol. 15, 313-320 (1996).	
	Roberts and Szostak. RNA-Peptide Fusions for the In Vitro Selection of Peptides and Proteins. PNAS 94, 12297-12302 (1997).	
	Rottgen and Collins. A Human Pancreatic Secretory Trypsin Inhibitor Presenting a Hypervariable Highly Constrained Epitope Via Monovalent Phagemid Display. Gene 164, 243-250 (1995).	
	Shibata et al. An Attempt to Substitute the Cell Binding Domain of Human Fibronectin in Lambda Phage J Protein: Computer Design and Expression. Biochimie. 75, 459-465 (1993).	
	Smith and Petrenko. Phage Display. Chem. Rev. 97, 391-410 (1997).	
	Tramontano et al. The Making of the Minibody: An Engineered Beta-Protein for the Display of Conformationally Constrained Peptides. J. Mol. Recog. 7, 9-24 (1994).	
	Wang et al. Isolation of a High Affinity Inhibitor of Urokinase-Type Plasminogen Activator by Phage Display of Ecotin. J. Biol. Chem. 270, 12250-12256 (1995).	
	Watanabe et al. Gene Cloning of Chitinase A1 From Bacillus Circulans WL-12 Revealed its Evolutionary Relationship to Serratia Chitinase and to the Type III Homology Units of Fibronectin. J. Biol. Chem. 265, 15659-15665 (1990).	
	Wells, J.A. Additivity of Mutational Effects in Proteins. Biochem. 29, 509-517 (1990).	
	Williams et al. The Immunoglobulin Superfamily - Domains for Cell Surface Recognition. Ann. Rev. Immunol. 6, 381-405 (1988).	
	Williams et al. Solution Structures of Modular Proteins by Nuclear Magnetic Resonance. Methods Enzymol. 245, 451-469 (1994).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	05/05
-----------------------	-------------------------------------------------------------------------------------	--------------------	-------




PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/728078
				Filing Date	December 3, 2003
				First Named Inventor	Dasa Lipovsek
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	COTH-P04-507

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
<i>[Signature]</i>	AN	US-6,383,775-B1	05-07-2002	Duff et al.	
<i>[Signature]</i>	AO	US-6,660,492-B1	12-09-2003	Bode et al.	
<i>[Signature]</i>	AP	US-2003/0104520-A1	06-05-2003	Ellington et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ² -Number ³ -Kind Code ³ (if known)	MM-DD-YYYY			
	AQ	-WO 03/022858-A2	03-20-2003			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
	AR	Bruzik, J. et al., "Spliced leader RNAs from lower eukaryotes are trans-spliced in mammalian cells," <i>Nature</i> 360, 692-695 (1992).				
	AS	Apte, et al., "Anchor-Ligated cDNA Libraries: A Technique for Generating a cDNA Library for the Immediate Cloning of the 5' Ends of mRNAs," <i>Biotechniques</i> 15, 890-893 (1993).				
	AT	Maruyama, K. et al., "Oligo-capping: a single method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides," <i>Gene</i> 138, 171-174 (1994).				
	AU	Brock, K. et al., "Nucleotide sequencing of 5' and 3' termini of bovine viral diarrhea virus by RNA ligation and PCR," <i>J. Virol. Methods</i> 38, 39-46 (1992).				
	AV	Ferguson, K. et al., "The SL1 trans-spliced leader RNA performs an essential embryonic function in <i>Caenorhabditis elegans</i> that can also be supplied by SL2 RNA," <i>Genes Dev.</i> 10, 1543-1556 (1996).				
	AW	Nielsen, T., "Trans-Splicing in Protozoa and Helminths," <i>Infect Agents Dis.</i> 1, 212-218 (1992).				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>[Signature]</i>	Date Considered	05/05
-----------------------	--------------------	--------------------	-------



PTO/SB/08a,b (03-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/728078		
		Filing Date	December 3, 2003		
		First Named Inventor	Dasa Lipovsek		
		Art Unit	1644		
		Examiner Name	Not Yet Assigned		
Sheet	1	of	1	Attorney Docket Number	COTH-P04-507

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ -Number ⁵ -Kind Code ⁶ (if known)				
AX		WO-99/51773	10-14-1999			
AY		WO-02/32925	04-25-2002			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
AZ		Roberts, R.W. Totally in vitro protein selection using mRNA-protein fusions and ribosome display. Current Opinion in Chemical Biology, Current Biology Ltd, London, GB, 3, 268-273 (1999), XP002180767 ISSN: 1367-5931.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	05/05
-----------------------	--	--------------------	-------